Product logins

Find logins to all Clarivate products below.


Blog: Biopharma

Here you will find relevant articles and insight into all Clarivate related products and news.

The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials
Five lessons learned deploying agentic AI in the life sciences Five lessons learned deploying agentic AI in the life sciences
Blog April 30, 2026
Five lessons learned deploying agentic AI in the life sciences
AI
Target selection and safety assessment: Navigating early decisions that shape drug development Target selection and safety assessment: Navigating early decisions that shape drug development
Blog March 27, 2026
Target selection and safety assessment: Navigating early decisions that shape drug development
Development Pharma Regulatory
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
Blog March 26, 2026
Drugs to Watch 2026 Q&A: Lilly’s next-generation weight loss drugs
GLP-1 Metabolic
Why longevity might be biopharma's next big thing: The science and business converge Why longevity might be biopharma's next big thing: The science and business converge
Blog March 2, 2026
Why longevity might be biopharma's next big thing: The science and business converge
Gerontology
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Relacorilant:  when evidence meets the established evidence bar Relacorilant:  when evidence meets the established evidence bar
Blog February 24, 2026
Relacorilant: when evidence meets the established evidence bar
FDA Regulatory Safety

Biopharma

Blog June 25, 2019
HealthHUBs: CVS-Aetna’s Expansion Into Primary-Care a Major Disruptor
Blog June 24, 2019
ASCO 2019: The future of Keytruda plus chemo combination therapy
Blog June 19, 2019
Will Netflix-Style Payment Models be the New Norm For High Cost Drugs?
Blog June 17, 2019
The Changing Specialty Drug Reimbursement Landscape
Blog June 10, 2019
Building A Market Access Advantage During Early Stage Development
Blog May 30, 2019
Growing Patient Involvement in Health Technology Assessment (HTA)
Cystic fibrosis: Market shake-up to come? Cystic fibrosis: Market shake-up to come?
Blog May 15, 2019
Cystic fibrosis: Market shake-up to come?
Oncology landscape stays hot for dealmakers Oncology landscape stays hot for dealmakers
Blog April 29, 2019
Oncology landscape stays hot for dealmakers
Drug development challenge: Managing CMC submissions Drug development challenge: Managing CMC submissions
Blog April 17, 2019
Drug development challenge: Managing CMC submissions
Blog April 10, 2019
Virginia and West Virginia Ban Copay Accumulators. What’s Next?